AGMB · Insider Trading
AgomAb Therapeutics NV American Depositary Shares
Every open-market purchase and sale reported by AGMB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-09 | David R Epstein | Director | Buy | +5,000 | +$44.50K |
| 2026-10-07 | David R Epstein | Director | Buy | +10,000 | +$86.35K |
| 2026-10-07 | Pierre Thadee Victor Kemula | Chief Financial Officer | Buy | +10,000 | +$85.94K |
| 2026-10-07 | Tim Jasper Knotnerus | Chief Executive Officer | Buy | +11,000 | +$94.38K |
| 2026-09-15 | Naimish Patel | Director | A | +56,328 deriv. | — |
| 2026-09-15 | Marino Garcia | Director | A | +57,482 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Tim Jasper Knotnerus | Chief Executive Officer | 56,217 | $462.67K |
| David R Epstein | Director | 15,000 | $123.45K |
| Pierre Thadee Victor Kemula | Chief Financial Officer | 8,000 | $65.84K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AGMB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.